” These data plainly demonstrate the security of high concentration NO dosed intermittently and follow the security seen to date in over 85 human topics treated with NO at concentrations of 160 ppm to 250 ppm,” specified Steve Lisi, CEO of Beyond Air. “We look forward to using these data to support our essential bronchiolitis research study planned for the 2020/21 winter in the United States and our 12-week nontuberculous mycobacteria study where patients will self-administer NO in the house.”
Beyond Air, Inc. (XAIR) just recently reported the effective completion of a 30-day rat toxicology research study and offered an upgrade on its 12-week toxicology studies in both canines and rats. All administrations in the studies were finished with LungFit & #x 2122;, the companys exclusive cylinder-free, phasic circulation NO generator and delivery system.
In both the 30-day rat research study and the 12-week rat and dog studies, animals were dosed periodically, multiple times per day with animals in the 30-day study receiving NO dosages of as much as 400 ppm. Outcomes from the 30-day study showed tidy safety results with no unforeseeable findings. The 12-week rat research study finished earlier this month, and the 12-week pet study remains in week 8 with animals getting NO doses of up to 250 ppm.
On 22 Oct 2019, Beyond Air Inc (NASDAQ: XAIR) started its trading session with the rate $4.5 and closed at rate of $4.17 by scoring -6.71%. XAIR has overall market capitalization of $44798310.
The brief ratio in the company stock is documented at 4.64 and the short float is around of 0.79%. The average real range of the stock is observed at 0.26 and the relative strength index of the stock is tape-recorded at 38.42.